Evidence map›Paper›PMID 39939877›Full record

SynthesisBMC cancer2025

Effect of alcohol consumption on oncological treatment effectiveness and toxicity in patients with cancer: a systematic review and meta-analysis.

Georgios Fountoukidis, Aglaia Schiza, Daniel Smith, Mukhrizah Othman, Marie Bergman, Johan Ahlgren, Mats Lambe, Sandra Irenaeus, Antonis Valachis

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Georgios Fountoukidis *Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, 702 81, Sweden.
Aglaia Schiza *Department of Oncology, Uppsala University Hospital, Uppsala, 751 85, Sweden. aglaia.schiza@igp.uu.se.
Daniel SmithClinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, 702 81, Sweden.
Mukhrizah OthmanDepartment of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, 702 81, Sweden.
Marie BergmanDepartment of Oncology, Hospital of Karlstad, Karlstad, 652 30, Sweden.
Johan AhlgrenRegional Cancer Centre, Mid-Sweden Health Care Region, Uppsala, 751 22, Sweden.
Mats LambeRegional Cancer Centre, Mid-Sweden Health Care Region, Uppsala, 751 22, Sweden.
Sandra IrenaeusRegional Cancer Centre, Mid-Sweden Health Care Region, Uppsala, 751 22, Sweden.
Antonis ValachisDepartment of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, 702 81, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlcohol consumption has been associated with an increased risk of cancer-related mortality. It may also negatively impact oncological therapies, potentially leading to impaired effectiveness or an increased risk of treatment-related toxicities. The aim of this systematic review and meta-analysis was to examine the current evidence regarding the potential effects of alcohol consumption during cancer treatments on both treatment effectiveness and toxicity, irrespective of cancer type.

methodsA comprehensive literature search was performed across three electronic databases (Medline, Web of Science, Cochrane) covering studies from January 1990 to December 2023. Furthermore, a manual search based on the reference lists of the eligible studies was performed to identify additional potentially eligible studies. Studies were eligible if they involved cancer patients and provided data on alcohol consumption during specific oncological treatments, including its effect on treatment outcomes, or compared treatment effectiveness or toxicity between drinkers and non-drinkers. Studies were excluded if they did not meet these criteria, were duplicates, case reports, conference abstracts, or focused only on cancer-specific or overall survival. Only studies using multivariable analyses to examine the association between alcohol consumption and treatment effectiveness or toxicity were included in the pooled analyses. Pooled Hazard Ratios (HRs) or Odds Ratios (ORs) and their corresponding 95% Confidence Intervals (CIs) were calculated using random-effects models. Study quality was assessed by using the Newcastle-Ottawa scale whereas the GRADE approach was applied to rate the certainty of evidence for pooled analyses.

resultsOut of 6734 studies identified through searching, 38 met the inclusion criteria for pooled analyses. Alcohol consumption during radiotherapy, with or without concomitant chemotherapy, was associated with worse disease-free survival (pooled HR: 2.05; 95% CI: 1.09 - 3.89), although the numerically increased risk for locoregional recurrence did not reach statistically significance (pooled HR: 2.01; 95% CI: 0.76 - 5.36). The potential impact of alcohol consumption on chemotherapy-induced neurotoxicity and acute / delayed nausea was not statistically significant. However, alcohol consumption was associated with a lower risk of overall chemotherapy-induced nausea (OR: 0.69; 95% CI: 0.57, 0.84).

conclusionOur findings suggest that alcohol consumption may have a negative impact on radiotherapy, whereas its potential impact on the effectiveness of systemic oncological therapies (chemotherapy, molecular targeted therapy, immunotherapy, endocrine therapy) has not been adequately studied. Similarly, the current evidence on the potential association between alcohol consumption and treatment-related toxicities is weak, highlighting the need for well-designed prospective studies on this topic.

Indexed as

Alcohol DrinkingNeoplasmsHumansTreatment OutcomeAlcohol consumptionCancer treatmentEffectivenessMeta-analysisToxicity

Identifiers

PMID39939877
PMCPMC11823036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.